Recursion Pharmaceuticals (NASDAQ:RXRX) Reaches New 1-Year Low – Should You Sell?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $3.77 and last traded at $3.7380, with a volume of 18343906 shares. The stock had previously closed at $4.10.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on RXRX. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Morgan Stanley set a $11.00 price target on Recursion Pharmaceuticals in a report on Wednesday, December 17th. JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th. Finally, UBS Group set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Price Performance

The firm has a market cap of $2.03 billion, a PE ratio of -2.17 and a beta of 0.95. The stock has a 50 day simple moving average of $4.49 and a two-hundred day simple moving average of $4.97. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The company had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $19.36 million. During the same period last year, the business earned ($0.34) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was down 80.1% on a year-over-year basis. Sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $4.36, for a total transaction of $959,200.00. Following the completion of the transaction, the director directly owned 6,649,863 shares of the company’s stock, valued at $28,993,402.68. The trade was a 3.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Najat Khan sold 124,403 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $4.41, for a total transaction of $548,617.23. Following the sale, the insider directly owned 611,135 shares in the company, valued at $2,695,105.35. This trade represents a 16.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 585,786 shares of company stock valued at $2,558,598 in the last 90 days. 8.43% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of RXRX. Norges Bank acquired a new position in Recursion Pharmaceuticals during the second quarter worth about $16,040,000. Bank Pictet & Cie Europe AG acquired a new position in shares of Recursion Pharmaceuticals during the 3rd quarter worth approximately $7,954,000. Stratos Wealth Partners LTD. grew its position in shares of Recursion Pharmaceuticals by 724.3% in the second quarter. Stratos Wealth Partners LTD. now owns 98,704 shares of the company’s stock valued at $499,000 after purchasing an additional 86,730 shares in the last quarter. Ethic Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the second quarter valued at approximately $107,000. Finally, Capital Fund Management S.A. lifted its position in Recursion Pharmaceuticals by 247.6% during the second quarter. Capital Fund Management S.A. now owns 720,526 shares of the company’s stock worth $3,646,000 after buying an additional 513,258 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.